10 July 2014Americas

Sanofi sues Eli Lilly to halt Lantus biosimilar

French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Awards USA returns for second year—with new categories

3 February 2026 Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.

Americas

Sanofi suffers setback in insulin monopoly dispute

29 January 2026 A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.

Americas

Eli Lilly’s Mounjaro tops list of cyber squatter targets

28 January 2026 The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.

More features

LSPN Awards USA returns for second year—with new categories

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Moderna VP and regulatory expert moves to private practice

Crowell adds tech partner with in-house and private practice expertise

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Pearce IP grows practice with senior patent hire

Sanofi suffers setback in insulin monopoly dispute

Firm adds seven-lawyer team in second major merger

Sanofi sues Eli Lilly to halt Lantus biosimilar

More on this story

Editor's picks

Editor's picks

More features